EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study

Emanuele Rando iD, Federica Salvati iD, Flavio Sangiorgi, Francesca Catania, Elisa Leone, Alessandra Oliva iD, Francesco Di Gennaro, Barbara Fiori, Francesca Cancelli, Sara Figliomeni, Francesca Bobbio, Federica Sacco und 7 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkad404 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Emanuele Rando und 18 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Sicurezza e Bioetica-Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy. Hauptthemen laut MEDLINE: Escherichia coli Infections, Sepsis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the impact of piperacillin/tazobactam MICs on in-hospital 30 day mortality in patients with third-generation cephalosporin-resistant Escherichia coli bloodstream infection treated with piperacillin/tazobactam, compared with those treated with carbapenems.

Methods

A multicentre retrospective cohort study was conducted in three large academic hospitals in Italy between 2018 and 2022. The study population comprised patients with monomicrobial third-generation cephalosporin-resistant E. coli bloodstream infection, who received either piperacillin/tazobactam or carbapenem therapy within 48 h of blood culture collection. The primary outcome was in-hospital 30 day all-cause mortality. A propensity score was used to estimate the likelihood of receiving empirical piperacillin/tazobactam treatment. Cox regression models were performed to ascertain risk factors independently associated with in-hospital 30 day mortality.

Results

Of the 412 consecutive patients included in the study, 51% received empirical therapy with piperacillin/tazobactam, while 49% received carbapenem therapy. In the propensity-adjusted multiple Cox model, the Pitt bacteraemia score [HR 1.38 (95% CI, 0.85–2.16)] and piperacillin/tazobactam MICs of 8 mg/L [HR 2.35 (95% CI, 1.35–3.95)] and ≥16 mg/L [HR 3.69 (95% CI, 1.86–6.91)] were significantly associated with increased in-hospital 30 day mortality, while the empirical use of piperacillin/tazobactam was not found to predict in-hospital 30 day mortality [HR 1.38 (95% CI, 0.85–2.16)].

Conclusions

Piperacillin/tazobactam use might not be associated with increased mortality in treating third-generation cephalosporin-resistant E. coli bloodstream infections when the MIC is <8 mg/L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coli InfectionsSepsisHumansCeftriaxoneCarbapenemsAnti-Bacterial AgentsPiperacillinEscherichia coliRetrospective StudiesPropensity ScorePenicillanic AcidPiperacillin, Tazobactam Drug CombinationCohort Studies

Substanzen

CeftriaxoneCarbapenemsAnti-Bacterial AgentsPiperacillinPenicillanic AcidPiperacillin, Tazobactam Drug Combination

Autor:innen und Institutionen

  • Dipartimento di Sicurezza e Bioetica-Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
  • Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Unit of Infectious Diseases, University of Bari 'A. Moro', Polyclinic Hospital, Bari, Italy.
  • Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
  • Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.

ORCID-Profile: Emanuele Rando, Federica Salvati, Alessandra Oliva

Zitieren

APA

Rando, E., Salvati, F., Sangiorgi, F., Catania, F., Leone, E., Oliva, A., Di Gennaro, F., Fiori, B., Cancelli, F., Figliomeni, S., Bobbio, F., Sacco, F., Bavaro, D. F., Diella, L., Belati, A., Saracino, A., Mastroianni, C. M., Fantoni, M., & Murri, R. (2024). Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad404

Vancouver

Rando E, Salvati F, Sangiorgi F, Catania F, Leone E, Oliva A, et al. Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkad404

BibTeX
@article{Rando2024,
  author = {Rando, Emanuele and Salvati, Federica and Sangiorgi, Flavio and Catania, Francesca and Leone, Elisa and Oliva, Alessandra and Di Gennaro, Francesco and Fiori, Barbara and Cancelli, Francesca and Figliomeni, Sara and Bobbio, Francesca and Sacco, Federica and Bavaro, Davide Fiore and Diella, Lucia and Belati, Alessandra and Saracino, Annalisa and Mastroianni, Claudio Maria and Fantoni, Massimo and Murri, Rita},
  title = {Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkad404}
}
Kostenlos starten →